Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 5/20 | 0.52 |
| ▸ | PARP1 | P09874 | 4/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.40 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.40 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.40 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4813967 | 0.81 | MAPK1 (0.56) | CHEK1PARP1POLBALDH1A1HTT | |
| SCHEMBL4809769 | 0.77 | RAB9A (0.50) | CHEK1PARP1RAB9APOLBCASP3 | |
| SCHEMBL4809861 | 0.74 | CHEK1 (0.52) | CHEK1ALDH1A1 | |
| SCHEMBL4809551 | 0.74 | CHEK1 (0.46) | CHEK1RAB9APOLBALDH1A1SMN1; SMN2 | |
| SCHEMBL4066767 | 0.73 | PARP1 (0.82) | PARP1RAB9ACASP3NPC1 | |
| SCHEMBL4814814 | 0.72 | PDGFRB (0.50) | CHEK1 | |
| SCHEMBL4808591 | 0.72 | CHEK1 (0.62) | CHEK1 | |
| SCHEMBL7698785 | 0.71 | CHEK1 (0.60) | CHEK1PARP1 | |
| SCHEMBL7698823 | 0.71 | CHEK1 (0.60) | CHEK1PARP1 | |
| SCHEMBL7092071 | 0.70 | PARP1 (0.62) | CHEK1PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7320986-B2 | Fused tri and tetra-cyclic pyrazole kinase inhibitors | ABBOTT LABORTORIES (US) | 2008-01-22 | — | — | US | disclosed |
| US-20040259904-A1 | Fused tri and tetra-cyclic pyrazole kinase inhibitors | ABBVIE INC. | 2004-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259904-A1 | Fused tri and tetra-cyclic pyrazole kinase inhibitors | TK1, MAP3K19, MAP3K20 | CHEK1 73/4885PARP1 946/4885RAB9A 2364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.